DiaMedica Therapeutics Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
DiaMedica amended and restated its 2019 Omnibus Incentive Plan, approved by the Board on March 16, 2026 and effective upon shareholder approval scheduled for May 20, 2026. The plan reserves 10.5 million shares for issuance under options, RSUs, and performance awards. Key terms include: maximum 2 million shares for Incentive Stock Options; non-employee director compensation capped at $400,000 annually ($600,000 for chair/lead director or initial year); standard vesting, exercise, and change-of-control provisions; and clawback provisions for accounting restatements and Dodd-Frank compliance. No specific dollar grants or share counts for existing awards are disclosed in this plan document.
Why this rating
Plan amendment is routine governance/administrative. 10.5M share reserve is ~2–3% of public float; immaterial relative to $95.8M market cap. No new money, material transaction, or business change disclosed.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.